The purpose of this document is to provide guidance for inclusion of costs for the drug of interest, its comparator(s) and concomitant drugs in pharmacoeconomic evaluations.  Drug costs should reflect the direct cost of the medicine to the HSE.

Guidelines for Inclusion of Drug Costs in Pharmacoeconomic Evaluations v3.1